The Medical Advisor

Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: October 13, 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of October 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side effects: what should patients know? Compounded, gray-market and research peptides: what are the risks? How strong is the evidence? (CEBM grades) Where to start: the complete GLP-1 evidence library Using...

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: October 2026 Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories (130 cases) Brain Cancer (including Glioblastoma) (135 cases) Bladder Cancer Success Stories  (including kidney cancer) (38 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (87 cases) Esophageal and Stomach cancer (23 cases) Endometrial Cancer (13 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer )  Head and Neck Cancer (17 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) Liver and Bile Duct Cancer  (Hepato-biliary system) (9 cases) Lung Cancer (63 cases) Leukemia (15 cases) Lymphoma (30 cases) Melanoma (refer to...